Ángel Lucio Pereira is Chief Executive Officer of Tetraneuron, a biotechnology company pioneering first-in-class gene therapies for Alzheimer’s disease and other neurodegenerative disorders. Under his leadership, the company has advanced its lead candidate, TET-101, into first-in-human clinical development, marking a major milestone in the treatment of neurodegenerative diseases. Ángel has more than 18 years of international experience in the pharmaceutical and biotech industry, having held leadership roles at Johnson & Johnson, Takeda and Sanofi across Europe and Asia, specializing in corporate strategy, business development, M&A and fundraising.